KRW 22450.0
(-1.54%)
Year | Eps | Eps Growth |
---|---|---|
2023 | 2096.33 KRW | 964.23% |
2022 | 200.32 KRW | -67.67% |
2021 | 619.55 KRW | 25.46% |
2020 | 493.83 KRW | 49.18% |
2019 | 331.03 KRW | 19.65% |
2018 | 276.67 KRW | -41.05% |
2017 | 469.33 KRW | 81.68% |
2016 | 258.33 KRW | 62.47% |
2015 | 159.00 KRW | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | 68.41 KRW | 145.56% |
2024 Q2 | 46.95 KRW | -31.37% |
2023 Q1 | 26.44 KRW | -67.14% |
2023 Q4 | -150.16 KRW | -106.84% |
2023 FY | - KRW | 964.23% |
2023 Q2 | 60.41 KRW | 128.48% |
2023 Q3 | 2195.17 KRW | 3533.79% |
2022 Q2 | 50.17 KRW | -10.41% |
2022 FY | - KRW | -67.67% |
2022 Q4 | 80.47 KRW | 473.15% |
2022 Q3 | 14.04 KRW | -72.02% |
2022 Q1 | 56.00 KRW | -84.83% |
2021 Q2 | 81.00 KRW | -6.9% |
2021 Q3 | 77.00 KRW | -4.94% |
2021 Q4 | 369.09 KRW | 379.34% |
2021 FY | - KRW | 25.46% |
2021 Q1 | 87.00 KRW | 0.0% |
2020 Q3 | 28.67 KRW | 8.89% |
2020 Q4 | - KRW | -100.0% |
2020 FY | - KRW | 49.18% |
2020 Q1 | 72.67 KRW | 0.0% |
2020 Q2 | 26.33 KRW | -63.77% |
2019 Q4 | - KRW | -100.0% |
2019 FY | - KRW | 19.65% |
2019 Q3 | 75.33 KRW | -19.86% |
2019 Q2 | 94.00 KRW | 29.96% |
2019 Q1 | 72.33 KRW | 0.0% |
2018 Q2 | 89.33 KRW | 27.61% |
2018 Q1 | 70.00 KRW | 0.0% |
2018 Q3 | 54.33 KRW | -39.18% |
2018 Q4 | - KRW | -100.0% |
2018 FY | - KRW | -41.05% |
2017 FY | - KRW | 81.68% |
2016 FY | - KRW | 62.47% |
2015 FY | - KRW | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 9148.00 KRW | 77.084% |
InBody Co.,Ltd | 2819.01 KRW | 25.636% |
Curexo Inc. | -120.00 KRW | 1846.942% |
Seegene, Inc. | 14.19 KRW | -14673.291% |
i-SENS, Inc. | 134.89 KRW | -1454.103% |
Ray Co., Ltd. | -140.25 KRW | 1594.709% |
Gencurix Inc. | -1629.25 KRW | 228.668% |
Sugentech Inc. | -1090.00 KRW | 292.324% |